Arovella Therapeutics Ltd (AU:ALA) — Market Cap & Net Worth
Market Cap & Net Worth: Arovella Therapeutics Ltd (ALA)
Arovella Therapeutics Ltd (AU:ALA) has a market capitalization of $58.08 Million (AU$82.09 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #21314 globally and #753 in its home market, demonstrating a -10.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arovella Therapeutics Ltd's stock price AU$0.07 by its total outstanding shares 1207183672 (1.21 Billion). Analyse cash efficiency ratio of Arovella Therapeutics Ltd to see how efficiently the company converts income to cash.
Arovella Therapeutics Ltd Market Cap History: 2015 to 2026
Arovella Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $425.37 Million to $58.08 Million (-18.02% CAGR).
Arovella Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arovella Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
584.09x
Arovella Therapeutics Ltd's market cap is 584.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $315.10 Million | $5.79 Million | -$2.23 Million | 54.46x | N/A |
| 2017 | $252.06 Million | $7.22 Million | -$1.24 Million | 34.90x | N/A |
| 2018 | $103.10 Million | $425.86K | -$5.46 Million | 242.09x | N/A |
| 2019 | $41.94 Million | $1.22 Million | -$7.80 Million | 34.40x | N/A |
| 2020 | $34.17 Million | $532.69K | -$9.94 Million | 64.14x | N/A |
| 2021 | $33.31 Million | $257.35K | -$5.05 Million | 129.44x | N/A |
| 2022 | $19.65 Million | $295.81K | -$8.62 Million | 66.41x | N/A |
| 2023 | $98.23 Million | $405.90K | -$10.18 Million | 242.00x | N/A |
| 2024 | $145.21 Million | $17.00K | -$8.75 Million | 8541.59x | N/A |
| 2025 | $79.44 Million | $136.00K | -$7.51 Million | 584.09x | N/A |
Competitor Companies of ALA by Market Capitalization
Companies near Arovella Therapeutics Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Arovella Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Arovella Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Arovella Therapeutics Ltd's market cap moved from $425.37 Million to $ 58.08 Million, with a yearly change of -18.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$58.08 Million | -26.88% |
| 2025 | AU$79.44 Million | -45.29% |
| 2024 | AU$145.21 Million | +47.83% |
| 2023 | AU$98.23 Million | +400.00% |
| 2022 | AU$19.65 Million | -41.03% |
| 2021 | AU$33.31 Million | -2.50% |
| 2020 | AU$34.17 Million | -18.53% |
| 2019 | AU$41.94 Million | -59.32% |
| 2018 | AU$103.10 Million | -59.10% |
| 2017 | AU$252.06 Million | -20.01% |
| 2016 | AU$315.10 Million | -25.92% |
| 2015 | AU$425.37 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Arovella Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.08 Million USD |
| MoneyControl | $58.08 Million USD |
| MarketWatch | $58.08 Million USD |
| marketcap.company | $58.08 Million USD |
| Reuters | $58.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more